OXFORD, England, Nov. 18, 2021 /PRNewswire/ -- PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, during an event last week at Seoul Yeouido SHIC tower, Seoul, South Korea.
Through this MOU, PharmaVentures and Shinhan Investment Corp intend to collaborate closely to provide a much broader range of capabilities and services to both Korean biotech companies and global biopharma companies looking at the Korean biotech opportunity. This will allow better access for the pharma and biotech industry to the financial services provided by Shinhan Investment Corp and the corporate advisory services provided by PharmaVentures who have reach into the global markets. The collaboration intends to give Korean companies better access to global markets, and for international companies to gain greater access to the Korean bio industry and its capital markets.
Adrian Dawkes, Managing Director at PharmaVentures said "We have been assisting many Korean biotech companies over the last 5 years and with our new collaboration with Shinhan Investment Corp we will be able to assist even more companies and bring the technology innovations of the Korean biotech sector to new audiences globally".
SHIC GIB Group Head Keunsoo Chung said, "Starting with this MOU, SHIC will assist bio ventures to successfully enter the capital market and provide differentiated investment banking services to mid-to-large size pharma to succeed in global biopharma industry. This MOU provides groundwork to improve the quality of strategic consulting and financial services for Korean bio/healthcare companies to innovate the IPO and M&A domains".
Fintan Walton, Founder and CEO of PharmaVentures, said "PharmaVentures has a long and strong history in supporting our clients in their deal making activities. Our specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms. We have the expertise to connect the Korean and Western Biopharma industries and vice versa, enabling them to collaborate through licensing and M&A deals."
South Korea is recognised as one of the leading nations for innovation, and Western pharmas are increasingly turning their attention to the rapidly expanding biotech sector there.
Examples of PharmaVentures work with Korean clients include:
Advisor to IntoCell throughout the initiation, negotiation, and execution of this multi-target collaboration agreement with Cellectar
Advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4
Valuation advisor to Yuhan Corporation on its licensing of Lazertinib for NSCLC to Janssen.